Publications & Conferences
-
EEV-Conjugated PMO Results in Nuclear Foci Reduction and Aberrant Splicing Correction in Myotonic Dystrophy Cell and Animal Models
- By:Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 27th International Annual Congress of the World Muscle Society (WMS)
-
Development of a Novel, EEV-Conjugated PMO for Duchenne Muscular Dystrophy
- By:Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: 27th International Annual Congress of the World Muscle Society (WMS)
-
A Novel Endosomal Escape Vehicle-Conjugated Oligonucleotide for Myotonic Dystrophy Type 1
- By:Xiulong Mark Shen, PhD, Senior Scientist, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
-
Development of a Novel Endosomal Escape Vehicle-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy
- By:Xiang Li, PhD, Associate Director, Discovery Research, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
-
Endosomal Escape Vehicle-Oligonucleotide Conjugates for the Targeted Upregulation and Downregulation of Gene Expression
- By:Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
-
Endosomal Escape Vehicles to Enhance the Functional Delivery of Oligonucleotides in Preclinical Models of Neuromuscular Diseases
- By:Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 2022 International Conference on Muscle Wasting
-
Development of a Novel, EEV-Conjugated PMO for Duchenne Muscular Dystrophy
- By:Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: 7th International Myology Congress
-
EEV-Conjugated PMO Results in Nuclear Foci Reduction and Aberrant Splicing Correction in Myotonic Dystrophy Cell and Animal Models
- By:Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 7th International Myology Congress
-
Introduction to Entrada Therapeutics and the Endosomal Escape Vehicle (EEV™) Platform to Enhance Oligonucleotide Delivery in Myotonic Dystrophy Type 1
- By:Michael Oldham, MD, Executive Medical Director, Entrada Therapeutics
- At: 2022 Myotonic Dystrophy Foundation (MDF) Annual Conference
